Advanced solid tumors
Conditions
Interventions
Experimental group:GM-CSF + radiotherapy
Sponsors
Affiliated Hospital of Medical College of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients aged 18 to 75 years; 2. Patients with stage IV metastatic malignant solid tumors diagnosed by pathological histology; 3. Patients with ECOG score = 3 months; 4. 1.0×10^9/L = 100g/L, platelets >= 80×10^9/L, serum transaminase not higher than 2.5 times the upper limit of normal value in patients without liver metastases, serum transaminase not higher than 5 times the upper limit of normal value in patients with liver metastases, serum bilirubin level not higher than 1.5 times the upper limit of normal value; serum creatinine level is not higher than 1.5 times the upper limit of normal value; 5. At least 2 lesions measurable by CT or MRI; 6. Sign the written informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who are allergic or hypersensitive to therapeutic agents, patients with autoimmune diseases; 2. Patients with only non-measurable lesions, such as thoracic ascites, cancerous lymphangitis, diffuse liver invasion, bone metastases; those with no measurable lesions or lesions that cannot be evaluated; 3. Pregnant or lactating women, those who are fertile but refuse to use contraception; 4. Uncontrolled symptomatic brain metastases or those with psychiatric abnormalities unable to correctly express subjective symptoms; 5. Those with significant organ failure; 6. Patients with factors affecting drug administration, absorption, distribution, metabolism, excretion, patients with uncontrollable seizures, central nervous system disorders or loss of self-awareness due to psychosis, patients with physiological or pathological malnutrition, chronic diarrhea, and cachexia; 7. Patients with complete or incomplete intestinal obstruction; 8. Patients with severe heart disease or history of disease, including: documented history of congestive heart failure, high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically definite heart valve disease, history of severe myocardial infarction, and intractable hypertension; 9. Serious uncontrollable infections; 10.Alcohol and/or drug abuse or poor compliance as judged by the investigator; 11.History of other malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lymphocyte subsets;Adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective remission rate; | — |
Countries
China
Contacts
Public ContactMa Xuezhen
Department of Oncology, the Second Affiliated Hospital of Medical College of Qingdao University
Outcome results
None listed